63-92-3

基本信息
盐酸苯氧苄胺
盐酸酚苄明
苯苄胺
苯氧苄胺
酚苄胺
竹林胺
盐酸酚芬明
酚苄明
BENZENE METHANAMINE HYDROCHLORIDE
DIBENZYLINE HYDROCHLORIDE
n-(2-chloroethyl)-n-(1-methyl-2-phenoxyethyl)benzenemethanamine hydrochloride
N-(2-CHLOROETHYL)-N-(1-METHYL-2-PHENOXYETHYL)BENZYLAMINE HYDROCHLORIDE
N-PHENOXYISOPROPYL-N-BENZYL-2-CHLOROETHYLAMINE HYDROCHLORIDE
PHENOXYBENZAMINE
PHENOXYBENZAMINE HCL
PHENOXYBENZAMINE HYDROCHLORIDE
bensylytnen
benzyl(2-chloroethyl)(1-methyl-2-phenoxyethyl)aminehydrochloride
dibenzyran
fenossibenzamina
fenoxybenzamin
n-(2-chloroethyl)-n-(1-methyl-2-phenoxyethyl)-benzenemethanaminhydrochlo
n-(2-chloroethyl)-n-(1-methyl-2-phenoxyethyl)-benzylaminhydrochloride
n-2-phenoxyisopropyl-n-benzyl-chloroethylaminehydrochloride
n-benzyl-n-phenoxyisopropyl-beta-chlorethylaminehydrochloride
nci-c01661
n-phenoxyisopropyl-n-benzyl-beta-chloroethylaminehydrochloride
物理化学性质
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2025/02/08 | HY-B0431A | 盐酸酚苄明 Phenoxybenzamine hydrochloride | 63-92-3 | 500mg | 300元 |
2025/02/08 | HY-B0431A | 盐酸酚苄明 Phenoxybenzamine hydrochloride | 63-92-3 | 10mM * 1mLin DMSO | 330元 |
2025/02/08 | HY-B0431A | 盐酸酚苄明 Phenoxybenzamine hydrochloride | 63-92-3 | 1g | 500元 |
常见问题列表
Target | Value |
α-adrenergic receptor |
The IC 50 (100 nM) derived from the blockade of [ 3 H]yohimbine binding by Phenoxybenzamine hydrochloride is significantly less than the IC 50 (550 nM) for the corresponding reversal by Phenoxybenzamine hydrochloride of the effects of norepinephrine on cyclic AMP accumulation. Phenoxybenzamine hydrochloride (50 nM) in conbination with Phenoxybenzamine hydrochloridetolamine (1000 nM) enhances Phenoxybenzamine hydrochlorideylephrine-induced contraction compared with pretreatment with Phenoxybenzamine hydrochloride (50 nM) alone in endothelium-intact aortae. Combined treatment with either dexmedetomidine (300 or 1000 nM) and Phenoxybenzamine hydrochloride (50 nM) or Phenoxybenzamine hydrochloridetolamine (1000 nM) and Phenoxybenzamine hydrochloride (50 nM) enhance Phenoxybenzamine hydrochlorideylephrine-induced contraction compared with Phenoxybenzamine hydrochloride alone (50 nM). In addition, combined treatment with Phenoxybenzamine hydrochloridetolamine and Phenoxybenzamine hydrochloride enhances Phenoxybenzamine hydrochlorideylephrine-induced contraction compared with dexmedetomidine (1000 nM) and Phenoxybenzamine hydrochloride combined treatment. Combined treatment with high concentrations of dexmedetomidine (1000 nM) and Phenoxybenzamine hydrochloride enhances Phenoxybenzamine hydrochlorideylephrine-induced contraction compared with combined treatment with low concentrations of dexmedetomidine (300 nM) and Phenoxybenzamine hydrochloride. Phenoxybenzamine hydrochloride (0.1-100 μM) inhibits glioma proliferation, migration, and invasion and suppresses the tumorigenesis capacity. Phenoxybenzamine hydrochloride also inhibits self-renewal of glioma stem-like cells. Phenoxybenzamine hydrochloride activates LINGO-1 and inhibits the TrkB-Akt pathway. Phenoxybenzamine hydrochloride (0.1 μM-1 mM) preserves primary neurons within the CA1, CA3 and dentate gyrus and produces a robust neuroprotective effect, and prevents neuronal death from OGD in all regions of the hippocampus when delivered at 2, 4, and 8 h post-OGD at 100 μM.
Phenoxybenzamine hydrochloride (20 nM, s.c.) effectively suppresses the tumorigenesis of glioma cells in mice and the cell density in Phenoxybenzamine hydrochloride-U87MG xenografts decreases significantly. Phenoxybenzamine hydrochloride (1 mg/kg, i.v.) treated rats shows significant improvements in NSS and foot fault scoring.